PMC:4504005 / 3491-4524 JSONTXT

{"project":"TEST0","denotations":[{"id":"25982113-235-243-8318988","span":{"begin":378,"end":382},"obj":"[\"21658025\", \"21658025\", \"21658025\"]"},{"id":"25982113-230-238-8318989","span":{"begin":399,"end":403},"obj":"[\"12037140\", \"12037140\", \"12037140\"]"},{"id":"25982113-150-158-8318990","span":{"begin":840,"end":844},"obj":"[\"20433208\", \"20433208\", \"20433208\"]"},{"id":"25982113-84-92-8318991","span":{"begin":955,"end":959},"obj":"[\"18998755\", \"18998755\", \"18998755\"]"},{"id":"25982113-156-164-8318992","span":{"begin":1027,"end":1031},"obj":"[\"12529940\", \"12529940\", \"12529940\"]"}],"text":"Although this model of binding is valid for several class B GPCRs, it cannot apply to all class B receptors. In particular, there are problems understanding the binding of members of the calcitonin (CT) family of peptides; calcitonin gene-related peptides alpha and beta (αCGRP, βCGRP), adrenomedullin (AM), adrenomedullin 2/intermedin (AM2), amylin (Amy), and CT (Hong et al., 2012; Poyner et al., 2002). These C terminally amidated peptides have a range of actions including neurogenic inflammation (CGRP), vasodilation/cardioprotection (CGRP, AM, and AM2), and regulation of blood and lymphatic vascular development (AM), nutrient intake and blood glucose (Amy), and bone turnover (CT). CGRP antagonists showed promise for the treatment of migraine and AM may be of value for the treatment of cardiovascular disorders (Durham and Vause, 2010; Karpinich et al., 2011). An Amy analog is used to treat insulin-dependent diabetes patients (Edelman et al., 2008) and CT has been long used to treat bone disorders (Purdue et al., 2002)."}

{"project":"2_test","denotations":[{"id":"25982113-21658025-118216091","span":{"begin":378,"end":382},"obj":"21658025"},{"id":"25982113-21658025-118216091","span":{"begin":378,"end":382},"obj":"21658025"},{"id":"25982113-12037140-118216092","span":{"begin":399,"end":403},"obj":"12037140"},{"id":"25982113-12037140-118216092","span":{"begin":399,"end":403},"obj":"12037140"},{"id":"25982113-20433208-118216093","span":{"begin":840,"end":844},"obj":"20433208"},{"id":"25982113-20433208-118216093","span":{"begin":840,"end":844},"obj":"20433208"},{"id":"25982113-18998755-118216094","span":{"begin":955,"end":959},"obj":"18998755"},{"id":"25982113-18998755-118216094","span":{"begin":955,"end":959},"obj":"18998755"},{"id":"25982113-12529940-118216095","span":{"begin":1027,"end":1031},"obj":"12529940"},{"id":"25982113-12529940-118216095","span":{"begin":1027,"end":1031},"obj":"12529940"},{"id":"25982113-21658025-71076100","span":{"begin":399,"end":403},"obj":"21658025"},{"id":"25982113-21658025-71076100","span":{"begin":399,"end":403},"obj":"21658025"},{"id":"25982113-12037140-71076100","span":{"begin":399,"end":403},"obj":"12037140"},{"id":"25982113-12037140-71076100","span":{"begin":399,"end":403},"obj":"12037140"},{"id":"25982113-20433208-71076101","span":{"begin":864,"end":868},"obj":"20433208"},{"id":"25982113-20433208-71076101","span":{"begin":864,"end":868},"obj":"20433208"},{"id":"25982113-18998755-71076102","span":{"begin":955,"end":959},"obj":"18998755"},{"id":"25982113-18998755-71076102","span":{"begin":955,"end":959},"obj":"18998755"},{"id":"25982113-12529940-71076103","span":{"begin":1027,"end":1031},"obj":"12529940"},{"id":"25982113-12529940-71076103","span":{"begin":1027,"end":1031},"obj":"12529940"}],"text":"Although this model of binding is valid for several class B GPCRs, it cannot apply to all class B receptors. In particular, there are problems understanding the binding of members of the calcitonin (CT) family of peptides; calcitonin gene-related peptides alpha and beta (αCGRP, βCGRP), adrenomedullin (AM), adrenomedullin 2/intermedin (AM2), amylin (Amy), and CT (Hong et al., 2012; Poyner et al., 2002). These C terminally amidated peptides have a range of actions including neurogenic inflammation (CGRP), vasodilation/cardioprotection (CGRP, AM, and AM2), and regulation of blood and lymphatic vascular development (AM), nutrient intake and blood glucose (Amy), and bone turnover (CT). CGRP antagonists showed promise for the treatment of migraine and AM may be of value for the treatment of cardiovascular disorders (Durham and Vause, 2010; Karpinich et al., 2011). An Amy analog is used to treat insulin-dependent diabetes patients (Edelman et al., 2008) and CT has been long used to treat bone disorders (Purdue et al., 2002)."}